Entero Healthcare operates a large-scale distribution platform that connects pharmaceutical and medical device manufacturers with retail pharmacies and hospitals across India. The company earns revenue by managing the supply chain, demand generation, and last-mile delivery of over 97,000 healthcare products.
The company possesses a network-effect moat driven by its scale, serving 1 in 10 Indian pharmacies and 3,600 hospitals, which makes it an essential partner for manufacturers. However, the low net margins (0.4%) and ROCE (7.9%) suggest that while the network is vast, it lacks significant pricing power or cost advantages over fragmented competitors.
Management aggressively pursues an inorganic growth strategy, acquiring over 45 regional distributors to build a national footprint. While this has successfully driven a 28.8% revenue CAGR, the historical return on equity remains low, indicating that the value of these acquisitions is still in the integration phase.
The aggressive roll-up strategy collapsed under its own weight as the company failed to integrate 45+ disparate regional distributors into a cohesive, high-margin operation. While revenue grew, the negative cash conversion cycle and heavy reliance on debt for inorganic expansion created a liquidity trap. Minority interest leakage and high interest costs eventually consumed the razor-thin 0.4% net margins, leading to a series of write-downs on the massive goodwill balance as the expected synergies from the national network failed to materialize in the bottom line.
RichFakir rates Entero Healthcare Solutions Ltd's business quality as mediocre — 48/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Entero Healthcare Solutions Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Entero Healthcare Solutions Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Entero Healthcare Solutions Ltd's fair value is about ₹225 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →